These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12781905)

  • 21. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].
    van den Meiracker AH
    Ned Tijdschr Geneeskd; 2008 Jun; 152(24):1358-60. PubMed ID: 18664211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
    Held C; Gerstein HC; Yusuf S; Zhao F; Hilbrich L; Anderson C; Sleight P; Teo K;
    Circulation; 2007 Mar; 115(11):1371-5. PubMed ID: 17339550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
    Böhm M; Baumhäkel M; Probstfield JL; Schmieder R; Yusuf S; Zhao F; Koon T;
    Am Heart J; 2007 Jul; 154(1):94-101. PubMed ID: 17584560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].
    Scheen AJ; Krzesinski JM
    Rev Med Liege; 2008 Apr; 63(4):213-9. PubMed ID: 18575077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].
    Oğuz A
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 6():4-12. PubMed ID: 20019467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
    Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
    Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
    Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
    J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular protection: a breakthrough for high-risk patients?
    Ferrari R
    J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons from ONTARGET.
    Berlaimont V; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Van Mieghem W; Vervaet P; Herman AG
    Acta Clin Belg; 2008; 63(3):142-51. PubMed ID: 18714845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
    Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
    Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
    N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-clinical and clinical experience of telmisartan in cardiac remodelling.
    Verdecchia P
    J Int Med Res; 2005; 33 Suppl 1():12A-20A. PubMed ID: 16222896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.